US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telomir Pharmaceuticals

1.14

0.0000

Post-market: 1.12-0.0246-2.16%18:17 EST

Volume:80.60K

Turnover:90.81K

Market Cap:39.19M

PE:-3.11

High:1.15

Open:1.13

Low:1.11

Close:1.14

52wk High:5.40

52wk Low:1.05

Shares:34.38M

Float Shares:15.33M

Volume Ratio:0.99

T/O Rate:0.53%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3665

EPS(LYR):-0.5597

ROE:-303.19%

ROA:-167.42%

PB:5.62

PE(LYR):-2.04

Loading ...

Overview Company News Filings

BRIEF-Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models

Telomir Pharmaceuticals Inc - Anticipates Ind Application Submission in Q1 2026 - SEC Filing

THOMSON REUTERS

Telomir Pharmaceuticals Inc - Iron-Rescue Experiments Confirm Tumor Cell Mortality Is Mechanistically Driven, Not Nonspecific Cytotoxicity

THOMSON REUTERS

Telomir Pharmaceuticals Targets 2026 IND Submission for Novel TNBC Therapy

Top News Today: Stocks Mixed After Muted Consumer Inflation

Telomir Pharmaceuticals Highlights Preclinical Data for Telomir-1

Telomir Pharmaceuticals Finds Lead Compound Balances Cellular Zinc and Iron in Preclinical Studies

Telomir Pharmaceuticals initiated with a Buy at Rodman & Renshaw

Nasdaq Warns Telomir Pharmaceuticals Over Delayed Annual Shareholder Meeting

BRIEF-Telomir Pharmaceuticals Telomir-1 Significantly Reduced Tumor Growth And Metastases

Telomir Pharmaceuticals: Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

THOMSON REUTERS

Telomir-1 Reduces Tumor Growth and Spread in Aggressive Triple-Negative Breast Cancer Models

Telomir Pharmaceuticals Approves New CEO Compensation Package Including Incentives and Salary Increase

Telomir Pharmaceuticals Inc - Reports Favorable Glp Safety Results for Telomir-1 - SEC Filing

THOMSON REUTERS

Telomir Pharmaceuticals Reports Positive Safety Results for Lead Drug Candidate Telomir-1

Telomir-1 Lowers PSA Levels and Reduces Tumor Volume in Prostate Cancer Studies

Telomir Pharmaceuticals Director Craig Eagle Resigns

Telomir Pharmaceuticals’ Telomir-1 Shows Leukemia Efficacy

Telomir Pharmaceuticals Inc. Announces Date for Upcoming Virtual Annual Meeting of Stockholders

Telomir-1 Kills Aggressive Human Leukemia Cells in Preclinical Study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TELO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TELO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TELO\",,,,,undefined,":{"symbol":"TELO","market":"US","secType":"STK","nameCN":"Telomir Pharmaceuticals","latestPrice":1.14,"timestamp":1771880400000,"preClose":1.14,"halted":0,"volume":80598,"hourTrading":{"tag":"盘后","latestPrice":1.1154,"preClose":1.14,"latestTime":"18:17 EST","volume":305,"amount":342.3730225,"timestamp":1771888622531,"change":-0.0246,"changeRate":-0.021579,"amplitude":0.026228},"delay":0,"changeRate":0,"floatShares":15328300,"shares":34380971,"eps":-0.366519,"marketStatus":"Post-Mkt","change":0,"latestTime":"02-23 18:42:38 EST","open":1.13,"high":1.15,"low":1.11,"amount":90814.3848654,"amplitude":0.035088,"askPrice":1.24,"askSize":100,"bidPrice":1.05,"bidSize":28,"shortable":3,"etf":0,"ttmEps":-0.366519,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771894800000},"marketStatusCode":4,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":1.14,"preHourTrading":{"tag":"盘前","latestPrice":1.13,"preClose":1.14,"latestTime":"09:26 EST","volume":887,"amount":1000.9283201,"timestamp":1771856775465,"change":-0.01,"changeRate":-0.008772,"amplitude":0.017544},"postHourTrading":{"tag":"盘后","latestPrice":1.1154,"preClose":1.14,"latestTime":"18:17 EST","volume":305,"amount":342.3730225,"timestamp":1771888622531,"change":-0.0246,"changeRate":-0.021579,"amplitude":0.026228},"volumeRatio":0.991387},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TELO\",,,,,undefined,":{"symbol":"TELO","floatShares":15328300,"roa":"-167.42%","roe":"-303.19%","lyrEps":-0.559686,"volumeRatio":0.991387,"shares":34380971,"dividePrice":0,"high":1.15,"amplitude":0.035088,"preClose":1.14,"low":1.11,"week52Low":1.05,"pbRate":"5.62","week52High":5.4,"institutionHeld":0,"latestPrice":1.14,"committee":-0.5625,"eps":-0.366519,"divideRate":0,"volume":80598,"delay":0,"ttmEps":-0.366519,"open":1.13,"prevYearClose":1.33,"prevWeekClose":1.14,"prevMonthClose":1.14,"prevQuarterClose":1.33,"fiveDayClose":1.09,"twentyDayClose":1.34,"sixtyDayClose":1.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TELO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-10","symbol":"TELO","fiscalQuarterEnding":"2025/09","expectedEps":-0.07,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2025-08-14","symbol":"TELO","fiscalQuarterEnding":"2025/06","expectedEps":-0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.17},{"market":"US","date":"2025-05-14","symbol":"TELO","fiscalQuarterEnding":"2025/03","expectedEps":-0.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2025-02-04","symbol":"TELO","fiscalQuarterEnding":"2024/12","expectedEps":-0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"post","actualEps":-0.1},{"market":"US","date":"2024-11-12","symbol":"TELO","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TELO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TELO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TELO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TELO","date":"2026-02-20","current":-3.110344,"percent":0.857988,"low":-83.265127,"twenty":-8.799568,"median":-5.894139,"eighty":-4.033896,"high":-2.36905,"avg":-9.36246,"sd":12.357462,"marketCap":38850497},"quantilePoints":[{"date":"2024-02-16","current":-56.39638,"twenty":-61.770129,"median":-49.049457,"eighty":-41.982417,"marketCap":238655100},{"date":"2024-02-23","current":-62.343889,"twenty":-63.029602,"median":-60.594622,"eighty":-46.922348,"marketCap":263823442},{"date":"2024-03-01","current":-63.46342,"twenty":-63.421438,"median":-62.588787,"eighty":-53.457611,"marketCap":268561012},{"date":"2024-03-08","current":-60.874505,"twenty":-63.351467,"median":-62.553802,"eighty":-58.915325,"marketCap":257605381},{"date":"2024-03-15","current":-45.550923,"twenty":-63.197532,"median":-61.749139,"eighty":-48.657621,"marketCap":192759889},{"date":"2024-03-22","current":-47.510102,"twenty":-63.029602,"median":-60.594622,"eighty":-45.928765,"marketCap":201050637},{"date":"2024-03-28","current":-35.580099,"twenty":-62.973626,"median":-56.39638,"eighty":-42.472212,"marketCap":150565904},{"date":"2024-04-05","current":-16.558518,"twenty":-62.833684,"median":-48.559663,"eighty":-36.881554,"marketCap":216450701},{"date":"2024-04-12","current":-18.574281,"twenty":-62.595784,"median":-46.390571,"eighty":-17.881143,"marketCap":242800474},{"date":"2024-04-19","current":-18.007992,"twenty":-62.469837,"median":-45.480952,"eighty":-18.234508,"marketCap":235398021},{"date":"2024-04-26","current":-15.402836,"twenty":-62.287913,"median":-41.632564,"eighty":-16.272973,"marketCap":201343774},{"date":"2024-05-03","current":-15.493668,"twenty":-61.8401,"median":-38.868721,"eighty":-15.530047,"marketCap":202531127},{"date":"2024-05-10","current":-14.814122,"twenty":-61.126399,"median":-34.985348,"eighty":-15.280653,"marketCap":193648183},{"date":"2024-05-17","current":-9.713938,"twenty":-60.762552,"median":-20.205194,"eighty":-14.460757,"marketCap":183044909},{"date":"2024-05-24","current":-9.899514,"twenty":-60.034856,"median":-18.959358,"eighty":-13.282876,"marketCap":186541828},{"date":"2024-05-31","current":-9.506677,"twenty":-58.635442,"median":-18.087272,"eighty":-12.474215,"marketCap":179139374},{"date":"2024-06-07","current":-8.846709,"twenty":-55.220872,"median":-16.988785,"eighty":-10.175947,"marketCap":166703252},{"date":"2024-06-14","current":-8.642433,"twenty":-50.224965,"median":-16.082609,"eighty":-9.764378,"marketCap":162853977},{"date":"2024-06-21","current":-8.249595,"twenty":-49.049457,"median":-15.652229,"eighty":-9.506677,"marketCap":155451523},{"date":"2024-06-28","current":-7.558201,"twenty":-48.069868,"median":-15.505107,"eighty":-8.846709,"marketCap":142423205},{"date":"2024-07-05","current":-6.803952,"twenty":-47.622055,"median":-15.431264,"eighty":-8.793283,"marketCap":128210494},{"date":"2024-07-12","current":-6.489682,"twenty":-46.614477,"median":-14.995334,"eighty":-8.611006,"marketCap":122288531},{"date":"2024-07-19","current":-5.892568,"twenty":-46.222641,"median":-14.134574,"eighty":-8.227596,"marketCap":111036802},{"date":"2024-07-26","current":-6.096844,"twenty":-45.67687,"median":-13.432376,"eighty":-7.822188,"marketCap":114886078},{"date":"2024-08-02","current":-5.248314,"twenty":-45.438969,"median":-12.639572,"eighty":-6.797667,"marketCap":98896778},{"date":"2024-08-09","current":-6.741098,"twenty":-44.067543,"median":-12.367753,"eighty":-6.690814,"marketCap":127026102},{"date":"2024-08-16","current":-6.303607,"twenty":-42.052388,"median":-10.284417,"eighty":-6.64996,"marketCap":118143157},{"date":"2024-08-23","current":-8.29422,"twenty":-40.401079,"median":-9.899514,"eighty":-6.678244,"marketCap":155451523},{"date":"2024-08-30","current":-8.278421,"twenty":-39.141606,"median":-9.736016,"eighty":-6.690814,"marketCap":155155425},{"date":"2024-09-06","current":-8.136234,"twenty":-38.861724,"median":-9.674022,"eighty":-6.712813,"marketCap":152490542},{"date":"2024-09-13","current":-9.589698,"twenty":-36.881554,"median":-9.506677,"eighty":-6.734812,"marketCap":179731570},{"date":"2024-09-20","current":-12.386034,"twenty":-35.223248,"median":-9.49882,"eighty":-6.759954,"marketCap":232140941},{"date":"2024-09-27","current":-10.774586,"twenty":-34.271647,"median":-9.637093,"eighty":-6.791381,"marketCap":201938931},{"date":"2024-10-04","current":-8.578593,"twenty":-25.750182,"median":-9.548188,"eighty":-6.888805,"marketCap":160781290},{"date":"2024-10-11","current":-8.009846,"twenty":-20.168951,"median":-9.479108,"eighty":-7.001943,"marketCap":150121756},{"date":"2024-10-18","current":-7.425301,"twenty":-19.534707,"median":-9.44751,"eighty":-7.071981,"marketCap":139166125},{"date":"2024-10-25","current":-7.01454,"twenty":-19.059025,"median":-9.384317,"eighty":-6.903527,"marketCap":131467574},{"date":"2024-11-01","current":-6.714368,"twenty":-18.728312,"median":-9.226332,"eighty":-6.834437,"marketCap":125841709},{"date":"2024-11-08","current":-6.666973,"twenty":-18.282076,"median":-8.941959,"eighty":-6.759954,"marketCap":124953415},{"date":"2024-11-15","current":-4.809979,"twenty":-18.039704,"median":-8.846709,"eighty":-6.708049,"marketCap":110444606},{"date":"2024-11-22","current":-5.467643,"twenty":-17.654627,"median":-8.799568,"eighty":-6.673736,"marketCap":125545611},{"date":"2024-11-29","current":-5.132363,"twenty":-17.074838,"median":-8.768141,"eighty":-6.632216,"marketCap":117847059},{"date":"2024-12-06","current":-8.407791,"twenty":-16.522185,"median":-8.642433,"eighty":-6.569924,"marketCap":193055987},{"date":"2024-12-13","current":-6.737953,"twenty":-16.313655,"median":-8.594391,"eighty":-6.600602,"marketCap":154713889},{"date":"2024-12-20","current":-6.712037,"twenty":-15.964821,"median":-8.461728,"eighty":-6.495967,"marketCap":154118835},{"date":"2024-12-27","current":-6.310352,"twenty":-15.760957,"median":-8.366804,"eighty":-6.403683,"marketCap":144895507},{"date":"2025-01-03","current":-5.856836,"twenty":-15.652229,"median":-8.303377,"eighty":-6.363974,"marketCap":134482072},{"date":"2025-01-10","current":-5.325574,"twenty":-15.570683,"median":-8.28632,"eighty":-6.315537,"marketCap":122283477},{"date":"2025-01-17","current":-6.077115,"twenty":-15.523297,"median":-8.249595,"eighty":-6.288654,"marketCap":139540026},{"date":"2025-01-24","current":-6.517673,"twenty":-15.50282,"median":-8.139601,"eighty":-6.28436,"marketCap":149655935},{"date":"2025-01-31","current":-6.297394,"twenty":-15.473282,"median":-8.073041,"eighty":-6.236001,"marketCap":144597981},{"date":"2025-02-07","current":-7.867,"twenty":-15.425578,"median":-8.088839,"eighty":-6.236001,"marketCap":130062872},{"date":"2025-02-14","current":-7.722981,"twenty":-15.280653,"median":-8.030693,"eighty":-6.247693,"marketCap":127681858},{"date":"2025-02-21","current":-7.038894,"twenty":-15.117652,"median":-7.97035,"eighty":-6.260979,"marketCap":116372043},{"date":"2025-02-28","current":-7.200915,"twenty":-14.922849,"median":-7.899257,"eighty":-6.280067,"marketCap":119050684},{"date":"2025-03-07","current":-7.830995,"twenty":-14.578546,"median":-7.867,"eighty":-6.294726,"marketCap":129467618},{"date":"2025-03-14","current":-8.245048,"twenty":-14.152696,"median":-7.888185,"eighty":-6.298884,"marketCap":136313033},{"date":"2025-03-21","current":-8.209043,"twenty":-13.908059,"median":-7.867,"eighty":-6.302115,"marketCap":135717779},{"date":"2025-03-28","current":-7.110904,"twenty":-13.595467,"median":-7.836063,"eighty":-6.306305,"marketCap":117562550},{"date":"2025-04-04","current":-5.27467,"twenty":-13.332709,"median":-7.821994,"eighty":-6.280067,"marketCap":87204626},{"date":"2025-04-11","current":-4.842615,"twenty":-12.988406,"median":-7.793903,"eighty":-6.226574,"marketCap":80061584},{"date":"2025-04-17","current":-4.464567,"twenty":-12.673549,"median":-7.741272,"eighty":-6.154861,"marketCap":73811424},{"date":"2025-04-25","current":-4.590583,"twenty":-12.555761,"median":-7.674628,"eighty":-6.056383,"marketCap":75894811},{"date":"2025-05-02","current":-4.662592,"twenty":-12.434833,"median":-7.63297,"eighty":-6.012327,"marketCap":77085317},{"date":"2025-05-09","current":-4.48257,"twenty":-12.382378,"median":-7.614926,"eighty":-5.935607,"marketCap":74109050},{"date":"2025-05-16","current":-5.972632,"twenty":-12.227313,"median":-7.558201,"eighty":-5.893196,"marketCap":74406677},{"date":"2025-05-23","current":-5.255916,"twenty":-11.632708,"median":-7.513523,"eighty":-5.862019,"marketCap":65477876},{"date":"2025-05-30","current":-5.017011,"twenty":-11.501318,"median":-7.475136,"eighty":-5.83092,"marketCap":62501609},{"date":"2025-06-06","current":-4.801996,"twenty":-11.15375,"median":-7.4411,"eighty":-5.738446,"marketCap":59822968},{"date":"2025-06-13","current":-4.778106,"twenty":-10.774586,"median":-7.421122,"eighty":-5.634716,"marketCap":59525342},{"date":"2025-06-20","current":-4.204733,"twenty":-10.62292,"median":-7.416943,"eighty":-5.48096,"marketCap":52382300},{"date":"2025-06-27","current":-4.06139,"twenty":-10.489162,"median":-7.344933,"eighty":-5.438999,"marketCap":50596540},{"date":"2025-07-03","current":-2.747411,"twenty":-10.309584,"median":-7.267316,"eighty":-5.403258,"marketCap":34227071},{"date":"2025-07-11","current":-2.795192,"twenty":-10.167924,"median":-7.19827,"eighty":-5.305212,"marketCap":34822325},{"date":"2025-07-18","current":-2.890754,"twenty":-10.119238,"median":-7.110904,"eighty":-5.252875,"marketCap":36012831},{"date":"2025-07-25","current":-5.470931,"twenty":-9.985876,"median":-7.051517,"eighty":-5.230053,"marketCap":68156516},{"date":"2025-08-01","current":-4.632645,"twenty":-9.902657,"median":-7.038894,"eighty":-5.134824,"marketCap":57713194},{"date":"2025-08-08","current":-4.137175,"twenty":-9.874769,"median":-6.990842,"eighty":-5.099417,"marketCap":51540660},{"date":"2025-08-15","current":-3.88944,"twenty":-9.817021,"median":-6.919749,"eighty":-5.017011,"marketCap":48454393},{"date":"2025-08-22","current":-3.011505,"twenty":-9.770664,"median":-6.814455,"eighty":-5.00486,"marketCap":48421455},{"date":"2025-08-29","current":-2.971351,"twenty":-9.7316,"median":-6.741098,"eighty":-4.932627,"marketCap":47775835},{"date":"2025-09-05","current":-2.489511,"twenty":-9.712744,"median":-6.725384,"eighty":-4.883224,"marketCap":40028402},{"date":"2025-09-12","current":-2.750508,"twenty":-9.681408,"median":-6.705303,"eighty":-4.805189,"marketCap":44224928},{"date":"2025-09-19","current":-2.810738,"twenty":-9.618135,"median":-6.678244,"eighty":-4.746437,"marketCap":45193358},{"date":"2025-09-26","current":-2.945698,"twenty":-9.55649,"median":-6.666973,"eighty":-4.681375,"marketCap":47363358},{"date":"2025-10-03","current":-2.924657,"twenty":-9.500391,"median":-6.651174,"eighty":-4.637423,"marketCap":47025048},{"date":"2025-10-10","current":-4.060855,"twenty":-9.486221,"median":-6.601898,"eighty":-4.590583,"marketCap":65293772},{"date":"2025-10-17","current":-3.408593,"twenty":-9.479108,"median":-6.517673,"eighty":-4.556077,"marketCap":54806171},{"date":"2025-10-24","current":-3.114023,"twenty":-9.472788,"median":-6.471284,"eighty":-4.524565,"marketCap":50069835},{"date":"2025-10-31","current":-3.156105,"twenty":-9.45067,"median":-6.414196,"eighty":-4.48257,"marketCap":50746455},{"date":"2025-11-07","current":-2.840494,"twenty":-9.412754,"median":-6.396899,"eighty":-4.45201,"marketCap":45671809},{"date":"2025-11-14","current":-3.909223,"twenty":-9.384317,"median":-6.363974,"eighty":-4.258858,"marketCap":43980261},{"date":"2025-11-21","current":-4.247815,"twenty":-9.364121,"median":-6.343714,"eighty":-4.249695,"marketCap":47789549},{"date":"2025-11-28","current":-4.095016,"twenty":-9.331287,"median":-6.313593,"eighty":-4.204733,"marketCap":46070501},{"date":"2025-12-05","current":-4.156135,"twenty":-9.283207,"median":-6.30112,"eighty":-4.101128,"marketCap":46758120},{"date":"2025-12-12","current":-4.522853,"twenty":-9.116263,"median":-6.282214,"eighty":-4.127895,"marketCap":50883837},{"date":"2025-12-19","current":-4.186695,"twenty":-9.035462,"median":-6.238265,"eighty":-4.127895,"marketCap":47101930},{"date":"2025-12-26","current":-4.339494,"twenty":-8.956704,"median":-6.222552,"eighty":-4.137175,"marketCap":48820978},{"date":"2026-01-02","current":-4.064456,"twenty":-8.944908,"median":-6.154861,"eighty":-4.119463,"marketCap":45726691},{"date":"2026-01-09","current":-4.339494,"twenty":-8.902896,"median":-6.1047,"eighty":-4.119463,"marketCap":48820978},{"date":"2026-01-16","current":-4.186695,"twenty":-8.85636,"median":-6.068194,"eighty":-4.119463,"marketCap":47101930},{"date":"2026-01-23","current":-4.095016,"twenty":-8.846892,"median":-6.038242,"eighty":-4.095016,"marketCap":46070501},{"date":"2026-01-30","current":-3.728298,"twenty":-8.846709,"median":-6.012327,"eighty":-4.082792,"marketCap":41944784},{"date":"2026-02-06","current":-3.422699,"twenty":-8.828026,"median":-5.986849,"eighty":-4.06323,"marketCap":38506687},{"date":"2026-02-13","current":-3.30046,"twenty":-8.805969,"median":-5.937145,"eighty":-4.036058,"marketCap":37131448},{"date":"2026-02-20","current":-3.453259,"twenty":-8.799568,"median":-5.894139,"eighty":-4.033896,"marketCap":38850497}],"updateTime":1771890158092},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TELO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612845749","title":"BRIEF-Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2612845749","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612845749?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:38","pubTimestamp":1771335535,"startTime":"0","endTime":"0","summary":"BRIEF-Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer ModelsFeb 17 (Reuters) - Telomir Pharmaceuticals Inc TELO.O:TELOMIR PHARMACEUTICALS INC - D","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD0CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2612527884","title":"Telomir Pharmaceuticals Inc - Anticipates Ind Application Submission in Q1 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612527884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612527884?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:12","pubTimestamp":1771333934,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD0CC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2612452223","title":"Telomir Pharmaceuticals Inc - Iron-Rescue Experiments Confirm Tumor Cell Mortality Is Mechanistically Driven, Not Nonspecific Cytotoxicity","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452223?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:12","pubTimestamp":1771333934,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD0CC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2612452981","title":"Telomir Pharmaceuticals Targets 2026 IND Submission for Novel TNBC Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452981","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452981?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:02","pubTimestamp":1771333338,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. announced plans to submit an Investigational New Drug  application for Telomir-Zn , a small-molecule therapeutic targeting triple-negative breast cancer , in the first quarter of 2026. Preclinical data show Telomir-Zn induces iron-dependent tumor cell mortality across multiple TNBC subtypes, with no treatment-related toxicity observed in GLP safety studies in rats and dogs. Additional studies, including a TNBC mouse xenograft model, are planned prior to the IND submission. Results from these studies will be presented in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL1zVzjw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2611919344","title":"Top News Today: Stocks Mixed After Muted Consumer Inflation","url":"https://stock-news.laohu8.com/highlight/detail?id=2611919344","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611919344?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:32","pubTimestamp":1771018320,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields declined following softer-than-expected U.S. consumer price index gains and ahead of a shortened week featuring the Fed's preferred inflation gauge.COMMODITIES: Crude oil futures settled higher, but still finished the week losing ground.Inflation Slowed to 2.4% in January, Helped by Lower Gasoline Prices. Consumer prices rose 2.4% in January from a year earlier, cooler than 2.7% in December and below the 2.5% economists surveyed by The Wall Street Journal had expected. Core prices, which exclude volatile food and energy items, rose 2.5% from a year earlier, in line with expectations.Former Microsoft and General Motors executive Chris Liddell, who helped take the automaker public, has joined Anthropic's board of directors, the company said.EV sales fell more than 30% in the fourth quarter, after a $7,500 federal tax credit that had juiced U.S. sales expired in September. Demand cratered for the highest-profile EVs, from Tesla's Cybertruck to Ford's much hyped ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4600","IE00BSNM7G36.USD","LU1868837300.USD","BK4107","LU1791807156.HKD","LU2471134879.HKD","BK4127","LU2237443978.SGD","BK4533","IE00BFXG1179.USD","FRMO","LU2237443382.USD","LU2237443465.HKD","LU2237443622.USD","LU2471134523.USD","PAMT","LU1868836757.USD","IE0002270589.USD","BK4136","BK4232","IE0004091025.USD","LU1894683264.USD","LU2750360997.AUD","LU2471134952.CNY","LU2237443549.SGD","SON","AHH","IE00B19Z3581.USD","LU0251142724.SGD","LU1804176565.USD","LU1868837136.USD","TELO","GSX","LU1894683348.USD","BK4081","LU2265009873.SGD","IE0034235188.USD","IE00B19Z3B42.SGD","BK4516","ITIC","LU1868836914.USD","LU2237438978.USD","OTTR","LU0048573561.USD","BK4588","LU0106831901.USD","BK4550","LU1868836591.USD","BK4160","LU2237443895.HKD"],"gpt_icon":0},{"id":"2609330837","title":"Telomir Pharmaceuticals Highlights Preclinical Data for Telomir-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2609330837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609330837?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:00","pubTimestamp":1770296455,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals, Inc. ( ($TELO) ) has issued an announcement. On February 5, 2026, Telomir Pharmaceuticals reported preclinical cellular da...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-highlights-preclinical-data-for-telomir-1?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-highlights-preclinical-data-for-telomir-1?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2609771713","title":"Telomir Pharmaceuticals Finds Lead Compound Balances Cellular Zinc and Iron in Preclinical Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2609771713","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609771713?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:32","pubTimestamp":1770294734,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced new preclinical cellular research results supporting the epigenetic modulation mechanism of its lead investigational compound, Telomir-1, in the form of Telomir-Zn. The data show that Telomir-Zn induces a coordinated redistribution of metals within cells, increasing intracellular zinc and reducing labile ferrous iron in a dose-dependent manner, without compromising cell viability. These effects were detected within 30 minutes of exposure and sustained for two hours. The findings suggest that Telomir-Zn may address key upstream drivers of cancer and aging by reducing oxidative stress and stabilizing epigenetic and mitochondrial function. The company has initiated manuscript submissions to peer-reviewed journals based on completed studies, with additional data from ongoing research still being generated. Telomir Pharmaceuticals plans to submit an Investigational New Drug application in the first quarter of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDLlf7Mr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2603630596","title":"Telomir Pharmaceuticals initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2603630596","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603630596?lang=en_us&edition=fundamental","pubTime":"2026-01-14 04:20","pubTimestamp":1768335648,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw initiated coverage of Telomir Pharmaceuticals (TELO) with a Buy rating and $8 price target Published first on TheFly – the ultimat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/telomir-pharmaceuticals-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/telomir-pharmaceuticals-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2603454281","title":"Nasdaq Warns Telomir Pharmaceuticals Over Delayed Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2603454281","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603454281?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:28","pubTimestamp":1768235309,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has received a notice from the Nasdaq Stock Market indicating non-compliance with Nasdaq Listing Rule 5620, which requires listed companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year. The company’s preliminary proxy statement is still under review by the Securities and Exchange Commission, delaying the annual meeting originally planned for December 30, 2025. Telomir has until February 23, 2026, to submit a compliance plan to Nasdaq and intends to hold the meeting promptly once the SEC review is complete, aiming to regain compliance and maintain its Nasdaq listing. The notice does not currently affect the trading or listing of the company’s shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLrvtTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2601883834","title":"BRIEF-Telomir Pharmaceuticals Telomir-1 Significantly Reduced Tumor Growth And Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2601883834","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601883834?lang=en_us&edition=fundamental","pubTime":"2026-01-05 23:16","pubTimestamp":1767626166,"startTime":"0","endTime":"0","summary":"BRIEF-Telomir Pharmaceuticals Telomir-1 Significantly Reduced Tumor Growth And Metastases Jan 5  - Telomir Pharmaceuticals Inc TELO.O:TELOMIR PHARMACEUTICALS: TELOMIR-1 SIGNIFICANTLY REDUCED TUMOR GROWTH AND METASTASES IN AGGRESSIVE TRIPLE-NEGATIVE BREAST CANCER ANIMAL MODELSSource text: [ID:n0001493152-26-000267]Further company coverage: TELO.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2601815028","title":"Telomir Pharmaceuticals: Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2601815028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601815028?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:06","pubTimestamp":1767618386,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2601881335","title":"Telomir-1 Reduces Tumor Growth and Spread in Aggressive Triple-Negative Breast Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2601881335","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601881335?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:02","pubTimestamp":1767618157,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced promising preclinical results for its investigational compound, Telomir-1 , in animal models of aggressive triple-negative breast cancer . The study, conducted in collaboration with BioReperia using zebrafish tumor xenograft models, showed that Telomir-1 significantly reduced primary tumor growth and the spread of cancer cells in models representing biologically distinct forms of TNBC. Notably, Telomir-1 was effective both as a monotherapy and in combination with the chemotherapy agent paclitaxel, particularly in models that were partially or not responsive to chemotherapy. These findings, which have already been completed and reported by the company, will inform future clinical trial designs and patient selection strategies as Telomir Pharmaceuticals continues its IND-enabling activities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL1FGYvg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2593890774","title":"Telomir Pharmaceuticals Approves New CEO Compensation Package Including Incentives and Salary Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2593890774","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593890774?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:03","pubTimestamp":1766401397,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced updated compensation terms for Chief Executive Officer Erez Aminov. The approved package includes a $400,000 short-term incentive payout based on 2025 company performance, and a contingent $150,000 milestone award tied to future FDA acceptance of the company's IND submission for Telomir-1. Additionally, Aminov will receive a transaction advisory award equal to 3% of the total value of the potential acquisition of TELI Pharmaceuticals, Inc., payable in cash, equity, or both at his discretion. His base salary will be set at $500,000 effective January 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL9DQP8C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2592943658","title":"Telomir Pharmaceuticals Inc - Reports Favorable Glp Safety Results for Telomir-1 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943658?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:03","pubTimestamp":1766005419,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN1BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2592943683","title":"Telomir Pharmaceuticals Reports Positive Safety Results for Lead Drug Candidate Telomir-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943683","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943683?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:02","pubTimestamp":1766005343,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced favorable results from a series of Good Laboratory Practice  toxicology and safety pharmacology studies for its lead therapeutic candidate, Telomir-1 . The studies, conducted in both in vitro systems and in vivo rat and dog models, found that Telomir-1 was generally well tolerated, with no treatment-related or dose-limiting toxicities observed. The company reported no adverse effects on cardiovascular, respiratory, or phototoxicity parameters, and any observed findings were limited, reversible, and considered non-adverse. Telomir Pharmaceuticals is preparing for the submission of an Investigational New Drug  application in the first quarter of 2026 and anticipates beginning first-in-human clinical studies in the first half of 2026. The company is also planning to submit scientific manuscripts for publication and to present data at multiple oncology-focused scientific conferences in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL3gc2fw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2586649089","title":"Telomir-1 Lowers PSA Levels and Reduces Tumor Volume in Prostate Cancer Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2586649089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586649089?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:02","pubTimestamp":1764018141,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced new preclinical data showing that its investigational compound, Telomir-1, significantly reduces prostate-specific antigen  levels in androgen-responsive human prostate cancer cells in vitro. PSA is an FDA-recognized biomarker for assessing prostate cancer treatment response, and Telomir-1 was found to lower PSA levels in a dose-dependent manner. The compound also demonstrated reductions in cellular energy metabolism and viability. Additional previously reported preclinical studies in a mouse model showed that Telomir-1 reduced tumor volume, both as a single agent and in combination with paclitaxel, with the combination resulting in no treatment-related mortality. These findings are part of Telomir's ongoing preclinical development efforts as the company prepares for an investigational new drug  submission. The announcement did not specify if or when these results will be presented at a scientific meeting.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL6hfvf7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2585633091","title":"Telomir Pharmaceuticals Director Craig Eagle Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2585633091","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585633091?lang=en_us&edition=fundamental","pubTime":"2025-11-21 06:16","pubTimestamp":1763676964,"startTime":"0","endTime":"0","summary":"Craig Eagle has resigned from the Board of Directors of Telomir Pharmaceuticals Inc., effective immediately.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 20, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL8YtdD9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2585829168","title":"Telomir Pharmaceuticals’ Telomir-1 Shows Leukemia Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2585829168","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585829168?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:35","pubTimestamp":1763674516,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). Telomir Pharmaceuticals announced that its investigational compound,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-telomir-1-shows-leukemia-efficacy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-telomir-1-shows-leukemia-efficacy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2585150586","title":"Telomir Pharmaceuticals Inc. Announces Date for Upcoming Virtual Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2585150586","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585150586?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:18","pubTimestamp":1763673505,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. will hold its Annual Meeting exclusively online via live audio-only webcast on December 30, 2025. During the meeting, stockholders will vote on matters submitted for approval, including proposals related to the business and operations of the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL108vXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2585157421","title":"Telomir-1 Kills Aggressive Human Leukemia Cells in Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157421?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:02","pubTimestamp":1763672558,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced new in vitro research results showing that its investigational compound, Telomir-1, effectively kills aggressive human leukemia  cells. These findings expand the oncology profile of Telomir-1 to include blood cancers, adding to previous evidence of activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. The study demonstrated that Telomir-1 reduces leukemia cell viability in a clear, dose-dependent manner and uniquely lowers intracellular iron levels, which leukemia cells rely on for growth and survival. The compound also inhibits key histone-demethylase enzymes and reduces abnormal DNA methylation of tumor-suppressor genes, supporting further oncology research by the company. The announcement does not specify if or when these results have been or will be presented at a scientific meeting.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL42980W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}